Menu
Search
|

Menu

Close
X

Innovate Biopharmaceuticals Inc INNT.OQ (NASDAQ Stock Exchange Capital Market)

1.97 USD
-- (--)
As of Mar 22
chart
Previous Close 1.97
Open --
Volume --
3m Avg Volume 88,795
Today’s High --
Today’s Low --
52 Week High 50.50
52 Week Low 1.70
Shares Outstanding (mil) 9.34
Market Capitalization (mil) 5.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
2
FY16
4
EPS (USD)
FY18
-1.069
FY17
-9.308
FY16
-8.111
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
1.94
8.39
Price to Book (MRQ)
vs sector
--
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
--
16.02
LT Debt to Equity (MRQ)
vs sector
--
11.35
Return on Investment (TTM)
vs sector
--
13.82
Return on Equity (TTM)
vs sector
--
15.24

EXECUTIVE LEADERSHIP

Sandeep Laumas
Executive Chairman of the Board, Chief Executive Officer, Since 2019
Salary: $137,000.00
Bonus: $132,500.00
Jay Madan
President, Chief Business Officer, Interim Principal Financial Officer, Interim Principal Accounting Officer and Director, Since 2018
Salary: $170,000.00
Bonus: $140,000.00
June Almenoff
Chief Operating Officer and Chief Medical Officer, Since 2018
Salary: --
Bonus: --
Stephen Brownsell
Executive Vice President, Since 2016
Salary: $153,769.00
Bonus: --
Lorin Johnson
Independent Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8480 Honeycutt Rd Ste 120
RALEIGH   NC   27615-2261

Phone: +1919.2751933
Site:

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.

SPONSORED STORIES